Quarterly report [Sections 13 or 15(d)]

Stock-based Compensation

v3.26.3
Stock-based Compensation
9 Months Ended
Sep. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation

Note 5 - Stock-based Compensation

 

On June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the “2019 Plan”). The 2019 Plan allows us, under the direction of our Board or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. The 2019 Plan provides for the aggregate issuance of 632,000 shares of our common stock. At September 30, 2026, we had 200,000 shares available for future grants.

 

Stock Compensation Expense

 

We recorded stock-based compensation expense for the three and nine months ended September 30, 2026 and 2025 as follows (in thousands):

 

    2026     2025     2026     2025  
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
Research and development   $ 179     $ 110     $ 213     $ 166  
General and administrative     667       193       821       568  
Total   $ 846     $ 303     $ 1,034     $ 734  

 

 

Stock Options

 

The following table summarizes our stock option activity during the nine months ended September 30, 2026:

 

    Total options
Outstanding
    Weighted
average
exercise price
    Weighted
average
remaining
contractual life
(in years)
 
Outstanding as of January 1, 2026     136,372     $ 13.43       9.8  
Options assumed in the Vidya Acquisition     1,047,524       0.01       9.4  
Outstanding as of September 30, 2026     1,183,896       1.56       9.3  
Exercisable as of September 30, 2026     58,745       19.59       9.3  

 

No forfeiture rate was applied to these stock options. The aggregate intrinsic value of outstanding options, other than those assumed in the Vidya Acquisition, was $0 at both September 30, 2026 and 2025. No stock options were exercised during the nine months ended September 30, 2026 or 2025. At September 30, 2026, unrecognized stock-based compensation expense for stock options of approximately $3.2 million is expected to be fully recognized over a weighted average period of 2.6 years.

 

Restricted Stock Units

 

Activity with respect to our restricted stock units (“RSUs”) during the nine months ended September 30, 2026 was as follows:

 

    Number of
shares
    Weighted-
average
grant-date fair
value per share
 
Outstanding at January 1, 2026     56,641     $ 31.02  
Granted     232,721       2.60  
Forfeited     (312 )     201.72  
Distributed, net     (6,836 )     173.39  
Outstanding at September 30, 2026     282,214       3.95  
Vested and unissued     (236,679 )     3.69  
                 
Unvested at September 30, 2026     45,535     $ 5.30  

 

On July 26, 2026, we granted RSUs that represent 232,721 shares of common stock to our employees and directors with a grant date fair value of $2.60. The RSUs vested immediately and the shares of common stock will be distributed within six months of the grant date. At September 30, 2026, unrecognized stock-based compensation expense of approximately $0.2 million for RSUs is expected to be fully recognized over a weighted average period of 2.0 years.

 

Holders of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their restricted stock unit award agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction on the holder. While certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a stockholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights.

 

 

Warrants

 

During the nine months ended September 30, 2026, warrants to purchase 27,065 shares of common stock expired or were cancelled. We did not grant any warrants and no warrants were exercised. We did not have any unrecognized stock-based compensation expense related to the 1,410,066 outstanding warrants at September 30, 2026. The outstanding warrants have a weighted average exercise price of $13.09 and expire between January 18, 2027 and July 18, 2030.